Metabolic Stress, AMPK–SQSTM1 Feedback, and Synergistic Antioxidant Responses in Tumor Adaptation

Study Background and Research Question

Tumor cells inhabit microenvironments marked by chronic nutrient depletion and oxidative stress, conditions that demand robust adaptive mechanisms to ensure survival and continued proliferation. The AMP-activated protein kinase (AMPK) pathway, activated under low energy states, and the KEAP1–NFE2L2/NRF2 antioxidant axis represent two central regulatory nodes in this adaptation. Notably, co-occurring mutations in STK11/LKB1 (the upstream kinase of AMPK) and KEAP1 are frequently observed in non-small cell lung cancer (NSCLC), yet the functional and mechanistic crosstalk between these pathways under metabolic stress has remained poorly defined. The 2024 study by Choi et al. set out to elucidate how metabolic stress orchestrates AMPK and NFE2L2/NRF2 activation, focusing on the role of the scaffolding protein SQSTM1/p62 in this regulatory network.

Key Innovation from the Reference Study

The central innovation of this work is the identification of a double-positive feedback loop between AMPK and SQSTM1/p62, which enables dual activation of AMPK- and NFE2L2/NRF2-driven antioxidant defenses under metabolic stress. Through this mechanism, SQSTM1 not only promotes the autophagic degradation of KEAP1—releasing NFE2L2/NRF2 from repression—but also facilitates AMPK activation by scaffolding the AXIN–STK11–AMPK complex on the lysosomal membrane. In turn, AMPK activity upregulates SQSTM1 expression and phosphorylation, forming a reciprocal regulatory loop. This synergistic system provides a molecular explanation for the frequent co-mutation of STK11 and KEAP1 in NSCLC and highlights new potential intervention points for modulating tumor adaptation.

Methods and Experimental Design Insights

The authors employed a combination of genetic, biochemical, and cell biological approaches in human and mouse cancer cell lines, including targeted knockouts, phosphorylation site mutagenesis, and pharmacological interventions to interrogate the feedback mechanisms between AMPK, SQSTM1, and NFE2L2/NRF2.

• Metabolic stress was induced by glucose deprivation and low-nutrient culture conditions, mimicking the tumor microenvironment.
• Phosphorylation states and protein-protein interactions were analyzed via immunoprecipitation and immunoblotting, allowing dissection of the AXIN–STK11–AMPK complex assembly and the role of SQSTM1 in KEAP1 degradation.
• Key phosphorylation sites on SQSTM1 (S24 and S226) were mutated to assess their necessity for AMPK and NFE2L2/NRF2 activation.
• Lysosomal function and acidification were perturbed using bafilomycin A1 and concanamycin A, while the impact of ROS and lysosomal Ca²⁺ release was evaluated using antioxidant and calcium chelation strategies.
• The involvement of protein phosphatases (PPP2/PP2A) and transcription factors (TFEB, TFE3) in SQSTM1 regulation was probed using both chemical inhibitors and siRNA knockdown.

Core Findings and Why They Matter

The study demonstrated that metabolic stress leads to increased expression and phosphorylation of SQSTM1/p62. This upregulation is essential for activating both AMPK and NFE2L2/NRF2, which together enhance antioxidant defense and tumor cell survival. Detailed mechanistic insights include:

• SQSTM1-driven Dual Activation: SQSTM1 promotes autophagic degradation of KEAP1 (releasing NFE2L2/NRF2) and, independently, scaffolds the AXIN–STK11–AMPK complex on lysosomes, promoting AMPK activation.
• Reciprocal Regulation: AMPK activity is necessary for metabolic stress-induced SQSTM1 expression and phosphorylation, establishing a double-positive feedback loop.
• Molecular Triggers: SQSTM1 expression is boosted by PPP2/PP2A-dependent dephosphorylation of TFEB/TFE3, themselves activated by lysosomal deacidification (a consequence of low glucose and AMPK-driven proton reduction).
• Phosphorylation Sites Criticality: Phosphorylation of SQSTM1 at S24 and S226 was required for full AMPK and NFE2L2/NRF2 activation.
• Functional Consequences: The feedback loop was abrogated by increased lactic acid (proton supply), pointing to the centrality of lysosomal pH in pathway regulation.

These findings clarify the adaptive landscape of tumor cells under metabolic stress, particularly in cancers with concurrent STK11 and KEAP1 mutations. The work provides a mechanistic framework that may inform targeted intervention strategies aimed at disrupting tumor antioxidant defenses.

Comparison with Existing Internal Articles

Several internal resources contextualize the practical significance of these mechanistic advances for sensory neuron and pain research workflows. For instance, "AMPK–SQSTM1 Feedback Enhances Antioxidant Response in Tumors" offers a concise overview of the core feedback mechanisms in the reference study, emphasizing the interplay between metabolic adaptation and oxidative stress resistance in cancer cells. Complementary articles such as "AMG 9810: Advanced TRPV1 Antagonist Workflows & Troubleshooting" and "AMG 9810: Applied TRPV1 Antagonist Workflows in Sensory Research" connect these mechanistic insights to practical assay design in pain and sensory neuron studies, where metabolic stress and calcium signaling play pivotal roles. These resources highlight the importance of assay reproducibility when exploring crosstalk between energy-sensing and oxidative stress pathways, especially in TRPV1-related research models.

Limitations and Transferability

While the reference study provides robust evidence in cell-based systems and draws mechanistic connections relevant to NSCLC, some limitations should be noted. The feedback loop was characterized predominantly in vitro, and its full implications in vivo—especially in the context of tumor heterogeneity and microenvironmental complexity—remain to be elucidated. Additionally, while the findings inform the molecular logic behind STK11 and KEAP1 co-mutations, direct therapeutic targeting of the AMPK–SQSTM1–NFE2L2 axis will require validation of druggability and pathway dependency in animal models and clinical samples. The molecular triggers described (e.g., lysosomal pH, ROS, Ca²⁺ signaling) may also vary across tissue types and disease contexts, potentially limiting the generalizability of the findings.

Protocol Parameters

• Metabolic stress induction: Glucose deprivation or low-nutrient media for 6–24 hours to model tumor-relevant stress conditions.
• Lysosomal pH manipulation: Use bafilomycin A1 (100 nM, 2–4 hours) to inhibit V-ATPase and induce deacidification; confirm with LysoTracker-based pH assays.
• SQSTM1 phosphorylation assessment: Employ site-directed mutagenesis (S24A, S226A) and immunoblotting to evaluate functional consequences on AMPK and NFE2L2/NRF2 activation.
• AXIN–STK11–AMPK complex visualization: Use co-immunoprecipitation and lysosomal fractionation to monitor complex assembly in response to stress.
• Antioxidant pathway functional readout: Measure NFE2L2/NRF2 nuclear translocation and target gene expression (e.g., NQO1, HO-1) as endpoints for pathway activation.

Research Support Resources

Researchers aiming to model aspects of sensory neuron signaling and metabolic stress adaptation can leverage advanced tools for precise pathway dissection. For instance, AMG 9810 (SKU B7018) is a potent and selective competitive TRPV1 antagonist that enables reproducible inhibition of capsaicin-induced calcium influx and CGRP release in sensory neuron studies. According to the product information, AMG 9810 exhibits nanomolar potency and is widely utilized in pain mechanism research, providing a robust platform for investigating metabolic and sensory pathway crosstalk. Proper solubility handling (≥33.7 mg/mL in DMSO) and storage at -20°C are recommended to maintain experimental integrity. Researchers can integrate such tools in conjunction with the mechanistic insights from the reference study to design more informative and reproducible metabolic stress experiments.